scientifyRESEARCH
research funding database

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

RESEARCH FUNDING

Kidney Cancer Research Program: Clinical Trial Award (worldwide)

Share

Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange plus symbol appears between the two logos.
Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange play symbol appears between the two logos. An arrow mark points to the logos.

The Kidney Cancer Research Program: Clinical Trial Award from the Congressionally Directed Medical Research Programs (CDMRP) supports the rapid implementation of clinical trials (phase 0, phase 1, phase 1/2) with the potential to have a significant impact on the treatment or management of kidney cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. The program is open to researchers in the USA and worldwide, including academic institutions and biotechnology companies. The award provides up to 1.5 million USD over 4 years. Indirect costs may be covered.

Funding Opportunity Number: HT9425-23-KCRP-CTA

Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), September 15, 2023. Application Submission Deadline: 11:59 p.m. ET, October 6, 2023.

Full application due:
October 6, 2023

non member

More related info for you

Register for free

Don´t have an account?

Start with our free trial to enjoy our 7 days of unlimited grant access and our premium features.

or, Choose a plan to subscribe to our premium membership.

Be the first to know

Sign-up for Personalized Grant alerts

Logo3

Sign-up for our
monthly research
funding newsletter

You can unsubscribe at any time.